other material
confidence high
sentiment positive
materiality 0.85
Trevi Therapeutics reports positive Phase 2b topline results for Haduvio in IPF chronic cough
Trevi Therapeutics, Inc.
- Primary endpoint met: 60.2% reduction in 24-hour cough frequency at 108 mg BID (p<0.0001) vs 16.9% placebo.
- Statistically significant improvements on cough-severity NRS and E-RS:IPF Cough Subscale at 108 mg and 54 mg BID.
- Discontinuation due to AEs similar between Haduvio (5.6%) and placebo (5.0%); safety profile consistent with prior trials.
- Expects end-of-Phase 2 FDA meeting in H2 2025; plans Phase 2b trial in refractory chronic cough starting H1 2026.
- Also plans to initiate clinical trial of Haduvio for non-IPF interstitial lung disease cough in H2 2025.